

- oral manifestations of, 237, 239t  
treatment of, 371
- Penciclovir, 215e-3t, 215e-8, 233, 1182t
- Pendred's syndrome, 220, 222t, 2284, 2284t
- Pendrin, 2284, 2284t
- Penetrance, 437, 446
- Penetrating radiation, 263e-1
- D-Penicillamine  
adverse effects of  
  autoimmune myasthenia gravis, 2702–2703  
  cutaneous, 349, 371, 379  
  lupus syndrome, 2218t  
  myopathy, 462e-20, 462e-20t, 2199, 2218t  
  optic neuropathy, 203  
  pyridoxine and, 96e-4  
  vasculitis, 2218t  
  zinc deficiency, 96e-10  
for cystinuria, 435e-2  
for mercury poisoning, 472e-3t  
for systemic sclerosis, 2164  
for Wilson's disease, 367e-2, 2519, 2520t, 2625
- Penicillin(s)  
for actinomycosis, 1090–1091, 1091t  
action of, 930, 931t, 937  
adverse effects of  
  acid-base disorders, 322  
  cross-sensitivity and, 385  
  cutaneous immunologic, 377  
  desensitization to, 385  
  erythema nodosum, 366  
  erythroderma, 353  
  hemolytic anemia, 44  
  hypokalemia, 306  
  neutropenia, 418  
  pemphigus, 371  
  platelet dysfunction, 730  
  rash, 362  
  seizure, 2547t, 2548  
  toxic epidermal necrolysis, 361  
  vasculitis, 2193  
for anaerobic bacterial infections, 1101  
for anthrax, 261e-3  
for asymptomatic pharyngeal GAS carriage, 966  
for bite-wound infections, 167e-3, 167e-3t  
for *Capnocytophaga* infections, 183e-2t, 183e-3  
for clostridial myonecrosis, 780t  
drug interactions of, 42–43  
for enterococcal infections, 975t  
for erysipelas, 965t  
for gas gangrene, 832t  
for GAS infections, 965t  
for group B *Streptococcus* infections, 970  
for group C or G streptococcal infections, 969  
for HACEK infections, 183e-2t  
for infective endocarditis, 821, 822t, 823  
for laryngitis, 234  
for leptospirosis, 1145t  
for meningococcemia, 780t  
for necrotizing fasciitis, 780t, 965t  
for pharyngitis, 232f, 233, 965t  
for pneumonia, 965t  
in pregnancy and lactation, 937t  
resistance to  
  in anaerobic bacteria, 1101  
  mechanisms of, 931t, 933  
  in meningococci, 1000  
  in *N. gonorrhoeae*, 1004  
  in pneumococci, 807  
for rheumatic fever, 2152  
for tetanus, 986  
for toxic shock syndrome, 965t
- Penicillin-binding proteins, 930, 947f, 976
- Penicillin G  
for diphtheria, 979  
for group B *Streptococcus* infections, 50, 970  
indications for, 937, 940t  
for Lyme disease, 1153, 1153f  
for meningitis, 887t, 889, 889t  
for neurosyphilis, 1139, 1139t  
for nongonococcal bacterial arthritis, 835  
for osteomyelitis, 840t, 841t  
for pharyngitis, 965t  
for pneumococcal infections, 952  
for relapsing fever, 1148, 1148f  
resistance to, 940t  
for staphylococcal infections, 962t  
for syphilis, 1138–1139, 1139t  
for syphilitic meningitis, 899
- Penicillin V, for diphtheria, 979
- Penicillium marneffei* infection (penicilliosis), 1252t, 1268, 1354–1355, 1354t
- Penile cancer, 351, 1198
- Penile prosthesis, 329
- Penile tumescence, 324
- Penile warts, 1198, 1199f
- Pentamidine  
action of, 246e-11, 332e-9  
adverse effects of  
  acid-base disorders, 321  
  bronchospasm, 1362t  
  frequent, 246e-6t, 1398  
  hyperkalemia, 64e-2, 310  
  hypotension, 1361  
  hypovolemia, 297  
  nephrotoxicity, 1804  
  occasional, 246e-6t, 1398  
  pancreatic, 1258  
  rare, 246e-6t  
  SA node dysfunction, 1467t  
for PCP, 1361t  
for PCP prophylaxis, 1251t, 1253, 1362t  
pharmacology of, 246e-11  
in pregnancy and lactation, 246e-6t  
for sleeping sickness, 1398, 1398t
- Pentasa, 1959
- Pentastomiasis, 2747
- Pentavalent antimonials, 246e-2t, 246e-7, 1390, 1393
- Pentazocine, 462e-20, 2218t
- Pentobarbital, 473e-10t, 2558f
- Pentosan polysulfate, 60e-3–4
- Pentoxifylline  
for alcoholic liver disease, 2053, 2054f, 2059  
for intermittent claudication, 1645
- Penumbra, 1777
- PEP. See Postexposure prophylaxis (PEP)
- PEPFAR (U.S. President's Emergency Plan for AIDS Relief), 8
- Pepsin, 1914
- Peptic ulcer disease, **1911**  
clinical features of, 96t, 100, 106t, 262, 1918  
complications of  
  bleeding  
    endoscopic treatment of, 1886, 1890, 1890f  
    incidence of, 1918  
    recurrent, prevention of, 276–277, 346e-1v, 1890, 1890f  
  gastric outlet obstruction, 1918  
  perforation, 1918  
  conditions related to  
    gastritis. See Gastritis  
    Ménétrier's disease, 534, **1932**  
    stress-related mucosal injury, 277, 1734, 1743, 1929–1930  
    Zollinger-Ellison syndrome. See Zollinger-Ellison syndrome (ZES)  
deaths from, 1911  
diagnosis of, 1918–1919  
  barium studies, 1919, 1919f  
  endoscopic, 1881, 1881f, 1886, 1895, 1919, 1919f  
  *H. pylori* detection, 1919, 1920t  
differential diagnosis of, 1918  
duodenal ulcers in. See Duodenal ulcers  
epidemiology of, 1911, 1914  
etiology of, 262, 1917–1918, 1918t  
gastroduodenal mucosal defense and, 1912–1913, 1912–1914  
genetic considerations in, 1917  
*H. pylori*-related. See *Helicobacter pylori* infections, in peptic ulcer disease  
NSAID-induced, **1916**  
  epidemiology of, 1916–1917  
  etiology of, 1917, 1917f  
  prevention of, 1923–1924, 1924t
- pathology of, 1915  
pathophysiology of, 1915  
in polycythemia vera, 673  
recurrence of, 1926  
risk factors for, 1914  
stomach cancer and, 534  
treatment of, **1919**, 1920t  
  antacids, 1920–1921  
  approach to, 1924, 1924f  
  bismuth-containing preparations, 1921  
  *H. pylori* eradication. See *Helicobacter pylori* infections, treatment of  
  H<sub>2</sub> receptor antagonists, 1920  
  NSAID-induced, 277, 1923–1924, 1923t  
  PPIs, 1920–1921  
  prostaglandin analogues, 1921  
  in refractory disease, 1924  
  sucralfate, 1921  
  surgical, 1925–1927, 1925f  
  ZES and, 568, 1927. See also Zollinger-Ellison syndrome (ZES)
- Peptide(s)  
antimicrobial, 372e-1, 372e-2, 372e-4t  
ovarian, 2378
- Peptide antigen, in HLA class I molecule, 373e-4
- Peptide nanostructures, 92e-1
- Peptide radioreceptor therapy (PRRT), 575
- Peptide YY, 415e-2
- Peptidoglycan, 145e-5, 145e-6f, 930, 1752
- Peptostreptococcus* spp. infections, 167e-2, 1095, 1099, 1100. See also Anaerobic bacterial infections, mixed
- Peramivir, 215e-5, 923, 1213
- Percent transferrin saturation, 627, 627f, 630t
- Perchlorate, 2300
- Percussion  
of chest, 47e-3, 1662  
of spleen, 411
- Percutaneous coronary interventions (PCI), **296e-1, 297e-1**  
for adult congenital heart disease, 296e-4  
antiplatelet agents in, 296e-1, 296e-2, 1596  
for aortic valve replacement. See Aortic valve replacement, transcatheter  
aortic valvuloplasty, 1533  
atherectomy, 296e-2  
for atrial septic defect repair. See Atrial septal defect (ASD), treatment of  
balloon angioplasty and stenting, 296e-1–2, 296e-1f  
for cardiogenic shock, 1762  
circulatory support during, 296e-5  
complications of, 296e-2–3, 1602t  
distal protection device for, 296e-2, 297e-3, 297e-3f, 297e-3v  
embolic protection device for, 296e-2  
Impella device for, 296e-5  
indications and patient selection for, 296e-3–4  
intimal dissection in, 296e-1, 296e-2f  
intraaortic balloon for circulatory support in, 296e-5  
vs. medical therapy in acute coronary syndromes, 296e-4  
mitral balloon valvotomy, 1542, 1542f  
mitral valve repair, 1546, 1546f  
for myocardial infarction  
  NSTEMI-ACS  
    left main in high-risk patient, 297e-3, 297e-3v  
    multivessel in diabetic patient, 297e-4, 297e-4v  
  patient selection, 296e-3f, 296e-4  
  rescue, 1605  
  STEMI. See ST-segment elevation myocardial infarction (STEMI), treatment of  
  time from symptom onset to, 1603, 1603f  
  urgent, 1605  
myocardial infarction related to, 296e-2  
perioperative, 52f, 53  
racial/ethnic disparities in referral for, 16e-2